Skip to content

Mesenchymal Stromal Cells and Osteoarthritis

Proliferation and Osteogenic Differentiation of Bone Marrow-derived Mesenchymal Stromal Cells From Osteoarthritic Versus Healthy Donors

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01038596
Enrollment
30
Registered
2009-12-24
Start date
2009-01-31
Completion date
2016-12-31
Last updated
2017-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoarthritis

Keywords

osteoarthritis, mesenchymal stromal cells, proliferation

Brief summary

Osteoarthritis (OA) is one of the most frequent musculoskeletal disorders and represents the main indication for total joint arthroplasty. Multipotent mesenchymal stromal cells (MSCs) can be easily isolated and culture expanded from bone marrow aspirates and provide an excellent source of progenitor cells for cell-based regeneration strategies due to their ex vivo differentiation and proliferation capacity. Although there are hints that MSCs derived from OA patients may exhibit altered function the role of MSCs with respect to disease development and progression of OA is not clearly understood to date. To assess whether advanced-stage OA affects MSCs' suitability for musculoskeletal regenerative therapy, in the present study, we compare proliferation and differentiation potential of MSCs from osteoarthritic versus healthy donors.

Detailed description

Clinical data (range of motion of lower limb joints, sociodemographic score dataset, WOMAC score, EQ-5D score, Harris Hip Score, radiological evaluation (OA group only), routine laboratory parameters, and bone metabolism parameters) Osteogenic, chondrogenic, and adipogenic differentiation is proofed qualitatively by cell staining osteogenic, chondrogenic and adipogenic marker gene expression analysis using quantitative real-time RT-PCR cell-specific alkaline phosphatase (ALP) activity assay large-scale gene expression profile Fluorescence-activated cell sorting (FACS)- CD44, CD105 (SH2; endoglin), CD106 (vascular cell adhesion molecule; VCAM-1), CD166, CD29, CD73 (SH3 and SH4), CD90 (Thy-1), CD117, STRO-1 and Sca-1 \[%\]

Interventions

None listed

Sponsors

German Federal Ministry of Education and Research
CollaboratorOTHER_GOV
Technische Universität Dresden
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
50 Years to 90 Years
Healthy volunteers
Yes

Inclusion criteria

* indication for hip THR * primary osteoarthritis of the hip * Patient's consent

Exclusion criteria

* secondary osteoarthritis of the hip * Any malignancies * infectious disease * rheumatic disease * osteoporosis * Any additional serious disease complicating the participation in this study

Design outcomes

Primary

MeasureTime frame
Global Gene expression profile of bone marrow-derived mesenchymal stromal cells from osteoarthritic versus healthy donorsafter msc isolation

Secondary

MeasureTime frame
Flow cytometric analysis of cell surface antigens, Alkaline phosphatase activity, DNA content as measure for cellular proliferationvariable 2 days up to 21 days after msc cultivation

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026